IL-BAI
19.8.2019 19:52:08 CEST | Business Wire | Press release
BAI announced the finalists for the 2019 BAI Global Innovation Awards, the industry’s most prestigious awards program that celebrates transformative solutions in the financial services industry worldwide.
Now in its ninth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. Through hundreds of applications, the Innovation Circle , a panel of global financial services innovation leaders who thoroughly review each application, determined the top submissions.
The judges weigh each innovation on originality and impact on consumers and the industry. This year’s finalists showcase what leading financial services innovators in all regions of the world are doing to deliver new value to customers and employees, as well as improve efficiencies and profitability for their organizations.
The 2019 BAI Global Innovation Awards finalists are:
Best Application of Advanced Technology in a Product or Service
- Emirates NBD, Dubai, United Arab Emirates: Emirates NBD Blockchain Center of Excellence for Payments
- ISBANK, Istanbul, Turkey: AI Personal Assistant “Maxi”
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: FiMAX Trade Finance Blockchain Network
- Yapı Kredi, Istanbul, Turkey: Financial Document Corrective Analysis
Business Model Innovation
- CaixaBank S.A., Barcelona, Spain: Travel Marketplace
- DenizBank, Istanbul, Turkey: DenizBank Banking as a Platform Initiative
- KASIKORNBANK PCL, Bangkok, Thailand: K PLUS Loyalty Card Platform
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Ventures
Human Capital Innovation
- Alior Bank S.A., Warsaw, Poland: Smartphonisation
- DenizBank, Istanbul, Turkey: Crowdfunding Platform, Fonosentez
- HDFC Bank, Mumbai, India: Recruitment Hackathon
- ISBANK, Istanbul, Turkey: Isbank Agile Atelier
- Ping An Insurance, Shenzhen, China: AI Interview System
Innovation in Customer Experience
- CaixaBank S.A., Barcelona, Spain: ATM Facial Recognition
- Commonwealth Bank of Australia, Sydney, Australia: Customer Experience Transformation via AI
- Emirates NBD, Dubai, United Arab Emirates: Customer Experience Month
- FNB Insurance, Johannesburg, South Africa: Claims Excellence
- The Bank of East Asia, Limited, Hong Kong: i-Planner
Innovation in Marketing
- CaixaBank S.A., Barcelona, Spain: imaginBank Agile Digital Marketing Room
- Elevate Credit, Fort Worth, Texas, U.S.: Elevate Credit Campaign 2019
- Fifth Third Bancorp, Cincinnati, Ohio, U.S.: Momentum Campaign
- ISBANK, Istanbul, Turkey: Maximum Gaming Esports Platform
- Pelican State Credit Union, Baton Rouge, Louisiana, U.S.: Pelican State of Mind
Innovation in Societal and Community Impact
- Absa Group Limited, Johannesburg, South Africa: Kongola
- BMO Harris Bank and Springfour, Chicago, Illinois, U.S.: BMO Harris - SpringFour Partnership
- JUMO.WORLD, Cape Town, South Africa: JUMO.WORLD
- Union Bank of the Philippines, Pasig, Philippines: Project i2i
Innovative Accelerator or Incubator
- Alior Bank S.A., Warsaw, Poland: RBL_START
- Citi Ventures, D10X, San Francisco, California, U.S.: D10X
- ISBANK, Istanbul, Turkey: Workup Entrepreneurship Program
- Royal Bank of Canada (RBC), Toronto, Canada: RBC Reach
- Woodforest National Bank, The Woodlands, Texas, U.S.: Woodforest Foundry
Innovative Touchpoints and Connected Experiences
- Aviva, Warsaw, Poland: Automated Claims Resolution Platform
- mBank S.A., Warsaw, Poland: Omni-channeling Asynchronous Chat
- Royal Bank of Canada (RBC), Toronto, Canada: DRIVE by RBC Ventures
Internal Process Innovation
- Alior Bank S.A., Warsaw, Poland: Smart Operations
- CommunityAmerica Financial Solutions, LLC, Lenexa, Kansas, U.S.: Dash360
- D10X, Citi, London, United Kingdom: Proxymity
- HDFC Bank, Mumbai, India: AI as a Service
- PKO Bank Polski, Warsaw, Poland: x-Platform
RegTech Innovation
- Hummingbird Regtech Inc, Walnut, California, U.S.: Regtech Solution
- Moody’s Analytics, San Francisco, California, U.S.: RiskFoundation™ Suite Hosted and Banking Cloud Solution
- Shenzhen OneConnect Smart Technology Co., Ltd, Shanghai, China: GAMMA Voiceprint Anti-fraud
- TSYS, Columbus, Georgia, U.S.: Foresight Score
- Yapı Kredi, Istanbul, Turkey: Digital Onboarding via Video Assistants
Congratulations to all the finalists of the BAI Global Innovation Awards. To learn more please visit BAIGlobalInnovations.com .
About BAI
As a nonprofit, independent organization, BAI delivers the financial services industry’s most actionable insights, enabling leaders to make smart business decisions every day. BAI is passionate about the trusted information and powerful tools that provide leaders with the clarity and confidence needed to drive positive change and move the financial services industry forward. For more information, visit www.bai.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190819005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom